NCT05239624View on ClinicalTrials.gov

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 2, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Urothelial Carcinoma
Interventions
DRUG

Enfortumab vedotin

Enfortumab vedotin will be administered at 1.25 mg/kg on day 1 and day 8 of each 21-day cycle, for up to 6 cycles.

DRUG

Pembrolizumab

Pembrolizumab will be administered on day 1 of each cycle, every 21 days, for 6 cycles.

Trial Locations (10)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

10604

RECRUITING

Memorial Sloan Kettering Westchester, Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau, Rockville Centre

11725

RECRUITING

Memorial Sloan Kettering -Nassau, Commack

18103

RECRUITING

Lehigh Valley Health Network (Data Collection Only), Allentown

33143

RECRUITING

Baptist Alliance MCI, Miami

75390

RECRUITING

University of Texas Southwestern Medical Center at Dallas, Dallas

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth, Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen, Montvale

All Listed Sponsors
collaborator

Astellas Pharma US, Inc.

INDUSTRY

collaborator

Seagen Inc.

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER